Exagen Inc Revenue Growth Rates (XGN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Exagen Inc   (NASDAQ: XGN)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

XGN's Revenue Growth by Quarter and Year

Exagen Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/XGN/growth
https://api.csimarket.com/api/v1/companies/XGN/fundamentals
https://api.csimarket.com/api/v1/companies/XGN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
XGN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 18.42
2nd Quarter June 19.94
1st Quarter March 17.21
FY 55.57

XGNs Annual Revenue
Exagen Inc 's Revenue in the fiscal year 2025 $ 65.80 millions
Exagen Inc 's Revenue in the fiscal year 2024 $ 55.11 millions
Exagen Inc 's Revenue in the fiscal year 2023 $ 52.55 millions
Exagen Inc 's Revenue in the fiscal year 2022 $ 45.56 millions
Exagen Inc 's Revenue in the fiscal year 2021 $ 48.30 millions




XGN Revenue third quarter 2026 Y/Y Growth Comment
Exagen Inc reported Revenue growth of 7.83% year on year in the third quarter 2026, to $ 18.42 millions, this is lower than Exagen Inc 's recent average Revenue growth of 9.43%.

Looking into third quarter 2026 results within Medical Laboratories industry 13 other companies have achieved higher Revenue growth. While Exagen Inc ' s Revenue increase of 7.83% ranks overall at the positon no. 976 in the third quarter 2026.


XGN Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 7.83 %
2nd Quarter June 21.59 %
1st Quarter March 13.82 %
FY   -

Financial Statements
Exagen Inc 's third quarter 2026 Revenue $ 18.42 millions XGN's Income Statement
Exagen Inc 's third quarter 2025 Revenue $ 17.08 millions Quarterly XGN's Income Statement


XGN Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -7.64 %
2nd Quarter June 15.86 %
1st Quarter March 0 %
FY (Year on Year)   -


Back to XGN Growth rate Comparisons >> Back to XGN Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #14
Healthcare Sector #196
Overall #976

Revenue Y/Y Growth Statistics
High Average Low
85.87 % 9.43 % -57.82 %
(Sep 30 2021)   (Jun 30 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #14
Healthcare Sector #196
Overall #976
Revenue Y/Y Growth Statistics
High Average Low
85.87 % 9.43 % -57.82 %
(Sep 30 2021)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Exagen Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
194.5 % 8.41 % -61.76 %
(Dec 31 2018)  


XGN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Exagen Inc disclosed drop in Revenue from the second quarter by -7.64% to $ 18.42 millions, from $ 19.94 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Exagen Inc 's Revenue growth quarter on quarter, overall rank is 618.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #5
Healthcare Sector #112
Overall #618
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #5
Healthcare Sector #112
Overall #618
Revenue Q/Q Growth Statistics
High Average Low
194.5 % 8.41 % -61.76 %
(Dec 31 2018)  


XGN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Exagen Inc disclosed drop in Revenue from the second quarter by -7.64% to $ 18.42 millions, from $ 19.94 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Exagen Inc 's Revenue growth quarter on quarter, overall rank is 618.


Exagen Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 72.77
Y / Y Revenue Growth (TTM) 17.9 %
Year on Year Revenue Growth Overall Ranking # 2557
Seqeuential Revenue Change (TTM) 1.88 %
Seq. Revenue Growth (TTM) Overall Ranking # 2373


Cumulative Revenue growth Comment
Assuming the Exagen Inc 's fiscal year would have ended in Sep 30 2026, Exagen Inc would have reprted above average annual Revenue increase of 17.9% year on year, of $ 73 millions.
This marks a slow-down of the companys growth trends and from the 24.98% improvement in Jun 30 2026.

In the Healthcare sector 367 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1882 to 2557.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 368
Overall # 2557

Revenue TTM Y/Y Growth Statistics
High Average Low
24.98 %
 6.9 %
-27.34 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 343
S&P 500 # 2373
Cumulative Revenue growth Comment
Assuming the Exagen Inc 's fiscal year would have ended in Sep 30 2026, Exagen Inc would have reprted above average annual Revenue increase of 17.9% year on year, of $ 73 millions.
This marks a slow-down of the companys growth trends and from the 24.98% improvement in Jun 30 2026.

In the Healthcare sector 367 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1882 to 2557.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 368
Overall # 2557

Revenue TTM Y/Y Growth Statistics
High Average Low
24.98 %
6.9 %
-27.34 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 343
S&P 500 # 2373




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XGN's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue improvement for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions
Privia Health Group Inc 13.19%$ 13.187 millions
Biocryst Pharmaceuticals Inc 13.11%$ 13.110 millions
U S Physical Therapy Inc12.90%$ 12.898 millions
Maravai Lifesciences Holdings Inc 12.78%$ 12.781 millions
Alphatec Holdings Inc 12.67%$ 12.670 millions
Harmony Biosciences Holdings inc 12.61%$ 12.609 millions
Medicinova Inc 12.35%$ 12.355 millions
Bionano Genomics Inc 12.34%$ 12.339 millions
Viemed Healthcare Inc 12.18%$ 12.180 millions
Ufp Technologies Inc 12.15%$ 12.154 millions
Innovage Holding Corp 12.14%$ 12.135 millions
Vertex Pharmaceuticals Inc11.85%$ 11.845 millions
Sanara Medtech Inc 11.67%$ 11.668 millions
Lemaitre Vascular Inc 11.51%$ 11.508 millions
Pacs Group Inc 11.45%$ 11.454 millions
Ocugen Inc 11.36%$ 11.358 millions
Dexcom Inc 11.26%$ 11.263 millions
Elanco Animal Health Incorporated11.26%$ 11.258 millions
Koru Medical Systems Inc 11.19%$ 11.194 millions
Elite Pharmaceuticals Inc 11.11%$ 11.113 millions
Pro dex Inc 10.96%$ 10.955 millions
Nrc Health10.95%$ 10.954 millions
Anika Therapeutics Inc 10.91%$ 10.912 millions
Harvard Bioscience Inc 10.86%$ 10.864 millions
Repligen Corp10.86%$ 10.863 millions
Warby Parker Inc 10.77%$ 10.767 millions


About Exagen Inc Revenue Growth Rates (XGN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Exagen Inc (CIK 1274737).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001274737-26-000065
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Exagen Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.